ABSTRACT
BACKGROUND: We sought to assess a novel, noninvasive, portable vagal nerve stimulator (nVNS) for acute treatment of migraine. METHODS: Participants with migraine with or without aura were eligible for an open-label, single-arm, multiple-attack study. Up to four migraine attacks were treated with two 90-second doses, at 15-minute intervals delivered to the right cervical branch of the vagus nerve within a six-week time period. Subjects were asked to self-treat at moderate or severe pain, or after 20 minutes of mild pain. RESULTS: Of 30 enrolled patients (25 females, five males, median age 39), two treated no attacks, and one treated aura only, leaving a Full Analysis Set of 27 treating 80 attacks with pain. An adverse event was reported in 13 patients, notably: neck twitching (n = 1), raspy voice (n = 1) and redness at the device site (n = 1). No unanticipated, serious or severe adverse events were reported. The pain-free rate at two hours was four of 19 (21%) for the first treated attack with a moderate or severe headache at baseline. For all moderate or severe attacks at baseline, the pain-free rate was 12/54 (22%). CONCLUSIONS: nVNS may be an effective and well-tolerated acute treatment for migraine in certain patients.
Subject(s)
Migraine Disorders/therapy , Vagus Nerve Stimulation , Adult , Female , Humans , Male , Pilot ProjectsABSTRACT
The development of an estimator for vapor pressure based upon organic functional groups is described. This vapor pressure calculator permits prediction of vapor pressure for a wide range of structural classes. The statistical quality of the derived coefficients is presented as well as the quality of the prediction of the training set of compounds. The calculator is then used to predict the vapor pressure of recently introduced agrochemicals to illustrate its performance. The significance of this calculator is that the agrochemical scientist can readily estimate the effects on vapor pressure of altering specific structural features of a molecule.